China's Hidden Hold on US Medicines Runs Deeper Than Finished Pills

Nearly 700 medicines depend on a chemical supplied only by China

Nearly 700 medicines used in the United States contain at least one necessary chemical supplied exclusively by China, according to the nonprofit US Pharmacopeia. They include amoxicillin, medicines for heart conditions and seizures, allergy treatments, and some cancer therapies. A disruption could reach from the household medicine cabinet to hospital intensive care.

As of November 27, 2025, the concern extends well beyond where a tablet is pressed or a vial is filled. China supplies many of the starting materials, reagents and solvents that manufacturers need to make active pharmaceutical ingredients, known as APIs. An API is the part of a medicine that produces its therapeutic effect.

US leaders have spent years examining dependence on China for rare earths and microchips. The chemicals behind everyday medicines present another strategic vulnerability, one that can remain hidden even when the finished product comes from India, Europe or North America.

The US-China Economic and Security Review Commission has urged Congress to give the Food and Drug Administration greater authority to collect information about the volume and origin of these chemicals. It has also pressed for purchasing policies that favor suppliers outside China where dependence is concentrated.

A trade dispute, sanctions episode or another major outbreak could interrupt ingredients used by American manufacturers and India's large generic drug industry. Companies are considering new US facilities, but many plans concern later manufacturing stages. The basic chemicals needed at the beginning remain among the tightest bottlenecks.

How the chemical chain reaches a pharmacy

A finished medicine is the last step in a much longer process. Production often begins in large reactors that make basic compounds. Manufacturers turn those compounds into key starting materials, process them into intermediates, and then produce the API.

Manufacturers combine that active ingredient with excipients, the other ingredients used to formulate the medicine, before testing, packaging and shipping the finished dose. Solvents and reagents help the chemical reactions and production steps take place. A factory needs these supporting chemicals as well as the ingredients that eventually go into the medicine.

The FDA closely regulates API manufacturing facilities and plants producing finished drugs. Oversight is less strict for upstream materials, including starting chemicals, reagents and solvents. Yet a shortage at that earlier stage can stop production at a plant farther along the chain.

China gained an early advantage through its large chemical industry, lower production costs and looser environmental rules. Over decades, purchasing teams settled on established Chinese suppliers, Indian API manufacturers built Chinese inputs into their production recipes, and distributors organized networks around those relationships.

Amoxicillin shows why the location printed on a finished medicine tells only part of the story. Its APIs and finished doses come from manufacturers in several countries, while several critical inputs come almost entirely from China. Multiple factories producing the same medicine can therefore share a vulnerable starting point.

Why different measures give different answers

FDA figures from 2019 showed that about 28 percent of API manufacturing sites supplying the US market were in the United States and roughly 13 percent were in China. The remaining sites were spread across Europe, India and other regions. The domestic share of sites was more than twice China's share, but those percentages describe locations, not production volumes.

A small facility and a large producer each count as one site. Many registered facilities or FDA filings also do not correspond to products actually sold in the United States. Public databases of API and finished dose facilities are useful, but incomplete for planning an emergency.

Estimates of China's API share range from single digits to figures closer to a quarter of US drug volume, depending on the method. The answer changes when researchers count facilities instead of volume, or include Chinese ingredients that reach the United States through another country.

US imports of APIs from China account for only a fraction of the total, while exposure in particular categories is much greater. Trade data and independent analyses show that the United States obtains the vast majority of its ibuprofen and a large share of its acetaminophen from China, along with substantial shares of penicillin class antibiotics.

Counting import value can also miss a public health vulnerability. Many essential generic medicines are inexpensive, so a modest amount of trade in dollar terms can support a large amount of patient care. Measuring quantities by medicine and treatment category gives planners a more useful picture of what could run short.

US Pharmacopeia has identified another concentration problem: half of the active ingredients used in the United States come from a single source. Its finding about nearly 700 medicines concerns a different layer, a necessary chemical available only from China. Those medicines include antihistamines kept at home and inexpensive treatments hospitals purchase in bulk.

The trade relationship runs in both directions. Trade in finished pharmaceuticals between the United States and China has grown, and the United States exports advanced biologics and immunological products to China. Dependence is uneven, with particular concern around upstream chemicals, antibiotics, inputs connected to cancer treatment, and other generics used in large quantities.

Why replacing suppliers is expensive and slow

Manufacturers of basic pharmaceutical chemicals operate with thin profits, high energy use and substantial environmental compliance costs. China's scale, integrated industrial parks and cost advantages drew production away from more expensive locations decades ago.

Established relationships then reinforced the pattern. Buyers had suppliers they knew, factories had production processes designed around particular inputs, and distributors had dependable routes. Building a parallel network requires more than opening a plant that makes finished tablets.

Industry executives estimate that reproducing some raw ingredient supply chains in the United States could increase costs by half for certain inputs. Generic medicines often sell at margins too narrow to absorb that premium easily. Restoring capacity in the United States or allied countries is therefore both expensive and slow.

Concentration also makes ordinary production problems harder to absorb. Maintenance at one site or a regulatory shutdown can leave other manufacturers without what they need, sending shortages through pharmacies and hospitals. Supply pressure existed before 2020, although the pandemic made the vulnerability more visible.

Quality failures at overseas factories have prompted recalls and temporary closures. US inspectors still encounter obstacles to frequent, unannounced inspections abroad. Watchdogs have also linked parts of the chemical supply chain in regions such as Xinjiang to forced labor concerns. The consequences reach beyond international politics to medicine availability, patient safety, ethical purchasing and price increases.

Three risks, from local shutdowns to strategic pressure

China's role creates three main kinds of risk: government pressure, accidental interruption and the loss of manufacturing capability. Each requires a different response, although all become harder to manage when many producers depend on the same chemicals.

Government pressure could involve threats to restrict exports during a confrontation. China's export control and biosecurity laws give it broad authority in this area. A blanket cutoff would be an extreme step that would also damage China, while targeted restrictions could still unsettle markets.

Accidental interruptions can begin in a single industrial cluster. A lockdown, fire, flood or electricity shortage can reduce supplies used around the world. During the pandemic, a pause at a major Shanghai plant producing diagnostic contrast media led hospitals worldwide to ration scans for months. Contrast media are used to help make internal structures visible during medical imaging.

The longer term concern is capability loss. If the United States and its allies give up more early and intermediate production stages, they can also lose practical chemical knowledge and skilled workers. That weakens their ability to expand advanced manufacturing for newer treatments.

A recent Pentagon assessment found that more than a quarter of medicines purchased for the US military draw on supply chains dependent on China in some way. Defense planners must account for those dependencies when preparing for emergencies and sudden increases in demand.

Leland Miller, a member of the US-China Economic and Security Review Commission, described the concern about ingredient dependence:

Beijing controls a scary chunk of active drug ingredients.

What the chronology reveals

The vulnerability developed over decades as basic chemical production shifted toward China and international buyers organized their purchasing around it. Several milestones show how the issue moved from an industrial pattern into a public health and national security concern.

• 2019: FDA data put about 28 percent of API sites supplying the United States at home and roughly 13 percent in China, offering a view of factory locations rather than the quantities produced.
• During the pandemic: Disruptions exposed the reach of concentrated production, including the Shanghai contrast media plant pause that led to months of scan rationing.
• By November 27, 2025: Proposals focused on broader FDA reporting, alternative suppliers, purchasing support and investment in manufacturing capacity.

Washington's agenda now combines better information with efforts to change where essential chemicals are made. The proposals described here have no stated deadline for congressional action, and the new US manufacturing plans have no stated completion dates.

Washington wants to see beyond the API factory

Proposals before Congress would expand FDA authority to require manufacturers to report the origin and volume of key starting materials, reagents and solvents, alongside information about API facilities. Regulators would gain a clearer view of the inputs that keep production running.

Such reporting could support maps of bottlenecks updated as supplies change, guide strategic stockpiles of essential medicines and chemicals, and help hospitals make purchasing decisions. Regulators are also encouraging manufacturers to qualify alternative suppliers in trusted jurisdictions and redesign formulations where feasible.

Carrie Harney, an official at US Pharmacopeia, described the purpose of greater visibility into these supply chains:

Our hope is that by having better data and more visibility, that can inform targeted interventions into creating resilience and security for patients.

Purchasing policy is another part of the proposed response. Steering orders toward suppliers outside China where risks are concentrated could give alternative producers a more dependable market. Stockpiles could provide a buffer while manufacturers restore production or shift to another qualified supplier.

Can public support make new plants viable?

The Department of Defense has experimented with agreements that set a minimum price for critical minerals to support domestic investment. Similar arrangements are being discussed for APIs and key starting materials. A producer would have greater confidence that a sudden drop in market prices would not make a new factory uneconomic.

Public financing, contracts covering purchases over many years and stockpiles shared among allies could reinforce that approach. These proposals address the commercial problem behind concentration: essential chemicals may be vital to health care while earning too little to attract competing producers.

Tariffs may discourage further concentration, but competing factories take time and investment to build. For many generic drugs, higher tariffs could instead produce higher prices or lead manufacturers to withdraw products.

The FDA continues to promote advanced manufacturing, including continuous flow processing. This approach moves material through connected production steps and can reduce costs, improve quality and reduce the space required for domestic manufacturing. New US facilities may help, although projects concentrated on later stages still need dependable sources for the chemicals used at the beginning.

India, Mexico and other partners face the same upstream test

India is the world's largest supplier of generic finished medicines and APIs, making it central to any effort to diversify. Many Indian manufacturers nevertheless depend on Chinese starting materials. Indian policies aim to rebuild domestic chemical capacity, a process that will take time.

Mexico offers proximity to the US market, an established medical manufacturing industry and room to expand production of APIs and finished medicines. Closer cooperation could include aligning regulatory requirements, conducting site inspections faster and directing incentives toward priority inputs.

Some US policymakers also support developing production with Middle Eastern partners, building on recent diplomatic accords to establish facilities serving American hospital systems. Europe remains another important partner, with strong quality standards and industrial parks available for specialty chemical production.

Each option can spread manufacturing across more locations. The decisive issue is what supplies those factories: a medicine finished in a partner country can still depend on a starting chemical made only in China. Diversification needs to reach the earliest bottlenecks rather than stop at the final production site.

How buyers could target the weakest points

Health systems and regulators need to connect each medicine to its API, the API to its starting materials, and those materials to the places where they are made. A finished dose from one country may contain an API from a second and chemicals from a third.

Lists of essential medicines could be paired with lists of essential inputs. Buyers could then arrange backup suppliers and inventory buffers at the precise points where a disruption would interrupt care. Group purchasing organizations, which buy on behalf of health providers, could use that information when negotiating contracts.

Digital tools that track products through the supply chain, supplier declarations about origin and labor practices, and dashboards combining customs information with regulatory filings could help buyers anticipate shortages. Measuring quantities by drug and treatment category would show where interruptions would affect patients most directly.

Partnerships between government and industry could support two qualified suppliers for critical starting materials, regional stockpiles of vulnerable inputs and financing for production in places with higher costs. The objective is a network with enough alternatives that a single company, region or production site cannot interrupt treatment for millions of people. China would remain part of that network, alongside a broader set of dependable suppliers.

Key Points

• US Pharmacopeia identified nearly 700 medicines that require at least one chemical supplied exclusively by China.
• Half of the active ingredients used in the United States come from a single source.
• FDA figures for 2019 put about 28 percent of API sites supplying the US market in the United States and roughly 13 percent in China; those figures count facilities rather than production volume.
• Chinese starting materials can supply factories in India, Europe and North America, extending dependence beyond direct US imports.
• Risks include export pressure, accidental shutdowns, quality problems and the loss of manufacturing skills and capacity.
• Proposals include broader FDA reporting, alternative suppliers, purchasing commitments, price support, stockpiles and advanced manufacturing.
• India, Mexico, Europe and Middle Eastern partners offer diversification options, but dependence persists when their factories require the same Chinese chemicals.